(Q42109216)

16 October 2017

A predictive probability design for phase II cancer clinical trials (English)

1 reference

16 October 2017

phase II clinical trial

0 references

author name string

J Jack Lee

series ordinal

1

1 reference

PMC publication ID

5626665

16 October 2017

Diane D Liu

series ordinal

2

1 reference

16 October 2017

1 January 2008

1 reference

16 October 2017

1 reference

16 October 2017

5

1 reference

16 October 2017

2

1 reference

16 October 2017

93-106

1 reference

16 October 2017

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Randomized phase II designs in cancer clinical trials: current status and future directions

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian sample size calculations in phase II clinical trials using informative conjugate priors

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Admissible two-stage designs for phase II cancer clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian methods in health technology assessment: a review

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Use of predictive probabilities in phase II and phase III clinical trials.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Data monitoring committees and problems of lower-than-expected accrual or events rates

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Multistage designs for phase II clinical trials: statistical issues in cancer research

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Recent developments in the design of phase II clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Multiple-stage procedures for drug screening.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Early decision in clinical trials when the treatment differences are small. Experience of a controlled trial in head trauma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Monitoring clinical trials: conditional or predictive power?

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Phase II trials in cancer: present status and analysis methods.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

A bayesian approach to the design of phase II clinical trials.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Monitoring clinical trials based on predictive probability of significance

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Optimal two-stage designs for phase II clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Planned versus attained design in phase II clinical trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Predictive Probability Early Termination Plans For Phase II Clinical Trials

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian designs with frequentist and Bayesian error rate considerations.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Clinical trials: is the Bayesian approach ready for prime time? Yes!

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian two-stage designs for phase II clinical trials

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Optimal flexible designs in phase II clinical trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Bayesian interim analysis of phase II cancer clinical trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

A unified method for monitoring and analysing controlled trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Practical Bayesian guidelines for phase IIB clinical trials.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Predictive probability in clinical trials

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5626665

Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts

17 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1177%2F1740774508089279

An optimal three-stage design for phase II clinical trials

21 January 2018

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

Applying a phase II futility study design to therapeutic stroke trials

1 reference

12 December 2020

Timing of futility analyses for 'proof of concept' trials

1 reference

12 December 2020

Graphical search for two-stage designs for phase II clinical trials

1 reference

12 December 2020

Optimal three-stage designs for phase II cancer clinical trials

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

Identifiers

DOI

10.1177/1740774508089279

1 reference

16 October 2017

1 reference

PMC publication ID

5626665

16 October 2017

PubMed publication ID

18375647

1 reference

PMC publication ID

5626665